Table 2.
Cardiovascular toxicity due to antineoplastic drugs
| Cardiovascular toxicity | Associated drugs |
|---|---|
| Heart failure | Doxorubicin, daunorubicin, idarubicin, epirubicin, mitoxantrone Cyclophosphamide, ifosfamide Docetaxel Trastuzumab, bevacizumab Sunitinib, pazopanib, sorafenib, imatinib, dasatinib, lapatinib, nilotinib Carfilzomib, Bortezomib |
| Myopericarditis | Cyclophosphamide 5-fluorouracil, cytarabine Trastuzumab, rituximab Interleukin-2 Immune-checkpoint inhibitors |
| Ischemic cardiomyopathy | 5-fluorouracil, capecitabine Cisplatin Paclitaxel, docetaxel Etoposide Bebacizumab Sorafenib, sunitinib Bleomycin |
| Atrial fibrillation | Cisplatin Cyclophosphamide, ifosfamide, melphalan Doxorubicin Capecitabine, 5-FU Gemcitabine Etoposide Paclitaxel Rituximab Sorafenib, sunitinib, ibrutinib Bortezomib Interleukin-2, interferon |
| Bradyarrhythmias | Cisplatin Cyclophosphamide, ifosfamide Doxorubicin, epirubicin, mitoxantrone Capecitanina, 5-FU Gemcitabine Paclitaxel Thalidomide Imatinib, bortezomib Rituximab Arsenic trioxide, interleukin-2 |
| Accelerated atherosclerosis | Bevacizumab, nilotinib, ponatinib Carfilzomib, bortezomib |
| Pericardial effusion | Cyclophosphamide Immune-checkpoint inhibitors1 |
| Venous thromboembolic disease | 5-fluorouracil Cisplatin Nilotinib, ponatinib, erlotinib Bevacizumab Vorinostat L-Asparaginase Immune-checkpoint inhibitors |
| Arterial thromboembolic disease | Cisplatin, carboplatin Gemcitabine Bleomycin Vincristine Nilotinib, ponatinib Bevacizumab Interferon alfa-2 Immune-checkpoint inhibitors |
| Arterial hypertension | Bevacizumab Sorafenib, sunitinib, axitinib, vandetanib, regorafenib |
| Pulmonary hypertension | Dasatinib Cyclophosphamide |
| Prolonged QT interval | Doxorubicin Depsipeptide, vorinostat Axitinib, cabozantinib, crizotinib, dasatinib, lapatinib, nilotinib, sorafenib, sunitinib, vandetanib, vemurafenib, ribociclib Arsenic trioxide |